TNP-470/minocycline/cytotoxic therapy: a systems approach to cancer therapy.
Teicher
B A
BA
Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Emi
Y
Y
Kakeji
Y
Y
Northey
D
D
D000818:Animals; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use; D015687:Cell Hypoxia / Q000187:drug effects; D002642:Chick Embryo; D003131:Combined Modality Therapy; D003510:Cyclohexanes; D004359:Drug Therapy, Combination; D006801:Humans; D051379:Mice; D008911:Minocycline / Q000627:therapeutic use*; D009369:Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*; D009389:Neovascularization, Pathologic / Q000188:drug therapy; D000077609:O-(Chloroacetylcarbamoyl)fumagillol; D011817:Rabbits; D051381:Rats; D012717:Sesquiterpenes / Q000627:therapeutic use*
D000900:Anti-Bacterial Agents; D000970:Antineoplastic Agents; D003510:Cyclohexanes; D012717:Sesquiterpenes; D008911:Minocycline; D000077609:O-(Chloroacetylcarbamoyl)fumagillol